Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial - Clinical Trials Arena
JPMorgan downgrades Sage Therapeutics stock on cautious outlook for Zurzuvae - Investing.com
JPMorgan downgrades Sage Therapeutics stock on cautious outlook for Zurzuvae - Investing.com
JPMorgan Downgrades Sage Therapeutics (SAGE) to Neutral - StreetInsider.com
JPMorgan Downgrades Sage Therapeutics (SAGE) to Neutral - StreetInsider.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE - PR Newswire
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails - Investor's Business Daily
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails - Investor's Business Daily
Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×